Caremo Named Among "Top 20 Chinese R&D CRO Enterprises in 2023"

The release and awards ceremony of the "2023 China Drug R&D Competitiveness Rankings" by Yaozh has concluded, with Caremo earning a place among the "Top 20 Chinese R&D CRO Enterprises in 2023".

Amidst growing policy emphasis on pharmaceutical R&D, drug innovation has become a lifeline for enterprises in the sector. Companies with robust R&D capabilities are poised to seize opportunities in the highly competitive and turbulent pharmaceutical market. As policies evolve continuously, enhancing R&D capacity and innovation agility remains imperative. Against the backdrop of China’s transition from a sales-driven to an R&D-driven pharmaceutical industry, the release of authoritative rankings such as the "Comprehensive Drug R&D Strength Rankings" carries significant strategic value.

Yaozh initiated and launched the "Comprehensive Drug R&D Competitiveness Rankings" through a multidimensional analysis of industry data, including:

- Comprehensive R&D capabilities

- Small-molecule drug development

- Biopharmaceutical R&D

- Brand influence

 

The evaluation criteria and ranking assessment for the "Top 20 Chinese R&D CRO Enterprises in 2023" incorporates multiple metrics, including:

- Annual Total Revenue

- Revenue Growth Rate (%)

- Net Profit

- Net Profit Growth Rate (%)

- R&D Investment

- R&D Investment Growth Rate (%)

- Workforce Size

- Workforce Expansion Rate (%)

Caremo’s inclusion in this prestigious list reflects recognition of its technical expertise, professional excellence, innovation capabilities, and growth performance. Moving forward, Caremo will collaborate with global biotech and pharmaceutical partners across the entire R&D value chain—from target validation to commercialization. By addressing clients’ diverse needs through flexible collaboration models, the company aims to deliver an integrated, end-to-end drug discovery and production service platform, providing comprehensive technological and industrialization support to advance global biopharmaceutical innovation.

 

"The path of drug innovation is arduous and long, but perseverance will lead us to the destination." Upholding our commitment to creating value and driving empowerment, we remain dedicated to fulfilling our corporate mission: "Born for Health, Empowered for Innovation".

 

· About Caremo

Nanjing Caremo Biomedical Co., Ltd., founded in June 2020 by Dr. Zhang Xiaoqing—a National “Ten Thousand Talents Plan” expert and former founder of Huawe Medicine—is headquartered in Nanjing. The company is dedicated to providing global biotech and pharmaceutical enterprises with integrated, customizable R&D solutions, spanning:

- Drug discovery

- Cell biology

- Pharmacology and efficacy studies

- Drug metabolism (DMPK)

- Preclinical safety evaluation

- CMC services

- Clinical trial research

- Customized development

- New drug incubation and investment

Caremo’s end-to-end, tailored solutions and full-cycle project management support partners in accelerating drug development from product initiation to commercialization. The company has assembled a 400+ member R&D team with extensive expertise in preclinical research and CMC (Chemistry, Manufacturing, and Controls). Over 11,000 sqm of chemistry and P2 laboratories compliant with China and U.S. regulatory standards, equipped with hundreds of advanced instruments, are operational. A 35,000 sqm R&D headquarters(with GLP-compliant lab) is currently under construction.

Leveraging its existing platforms, Caremo aims to collaborate with domestic and international biotech and pharmaceutical companies across the entire R&D value chain—from target validation to commercialization. By addressing diverse client needs and embracing flexible partnership models, Caremo will provide a comprehensive, end-to-end drug discovery and production service platform, delivering full-spectrum technological and industrial support to advance global biopharmaceutical innovation.